Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer

[1]  P. Neven,et al.  A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy , 2008, Breast Cancer Research and Treatment.

[2]  M. Dowsett,et al.  The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo , 2007, Molecular Cancer Therapeutics.

[3]  M. Ellis,et al.  The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers , 2007, Breast Cancer Research and Treatment.

[4]  E. Tokunaga,et al.  Activation of PI3K/Akt signaling and hormone resistance in breast cancer , 2006, Breast cancer.

[5]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[6]  M. Dowsett,et al.  Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Dowsett,et al.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[10]  M. Dowsett,et al.  Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance , 2005, Breast Cancer Research and Treatment.

[11]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Schellens,et al.  Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.

[13]  Albino Martins,et al.  Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression , 2005, Breast Cancer Research.

[14]  M. Fernö,et al.  Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[16]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[17]  R. Kumar,et al.  Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. , 2005, Endocrine-related cancer.

[18]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[19]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Simak Ali,et al.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. , 2005, The Lancet. Oncology.

[21]  E. Rowinsky,et al.  A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients , 2005 .

[22]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[23]  Xin Huang,et al.  Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.

[24]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[25]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[26]  R. Chibbar,et al.  Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen , 2005, Modern Pathology.

[27]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Venzon,et al.  A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  K. Blackwell,et al.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. , 2005, Cancer research.

[30]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[32]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[33]  F. Khuri,et al.  Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? , 2004, Endocrine-related cancer.

[34]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[35]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[36]  R. Nicholson,et al.  The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. , 2003, Endocrinology.

[37]  M. Dowsett,et al.  Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.

[38]  W. Carney,et al.  Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Baselga,et al.  ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[41]  Simak Ali,et al.  Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.

[42]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[44]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[46]  J. Herman,et al.  Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. , 2000, Cancer research.

[47]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[48]  Ji-ping Wang,et al.  Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells , 2000, Breast Cancer Research and Treatment.

[49]  M. Karkkainen,et al.  Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.

[50]  C. Osborne,et al.  Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. , 1997, Cancer research.

[51]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[52]  C. Der,et al.  Aberrant function of the Ras signal transduction pathway in human breast cancer , 1995, Breast Cancer Research and Treatment.

[53]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[54]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[55]  Thomas H. Maugh,et al.  Breast Cancer Research , 1978, British Journal of Cancer.

[56]  A. Giordano,et al.  Epigenetic information and estrogen receptor alpha expression in breast cancer. , 2006, The oncologist.

[57]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.